Condition: Anterior Cruciate Ligament Reconstruction · Sponsor: The Methodist Hospital Research Institute
This study is designed as a prospective, open label, single arm pilot clinical study that will establish the safety and efficacy of a single injection of mesenchymal stromal cells in patients. Each subject will receive one intra-articular injection of autologous mesenchymal stromal cells derived from infrapatellar fat pad (FP-MSC) tissue samples collected from the subject during anterior cruciate ligament (ACL) reconstruction surgery.
This description comes directly from the study's public registry record.
Madison Bowden · 713-363-7390 · mmbowden@houstonmethodist.org
Haley Goble · 713-441-3930 · hmgoble@houstonmethodist.org
Always discuss trial participation with your own doctor first.
| Houston Methodist Hospital | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06798623